Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients34

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients22

Views

Views
October 20240
November 20240
December 20242
January 20253
February 20250
March 202517
April 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore17
United States2
United Kingdom2
Canada1
 

Top cities views

Views
Houston2
Toronto1